KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Change in Accured Expenses (2018 - 2025)

ClearPoint Neuro's Change in Accured Expenses history spans 13 years, with the latest figure at $693000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 7.11% year-over-year to $693000.0; the TTM value through Sep 2025 reached $481000.0, down 72.47%, while the annual FY2024 figure was $3.1 million, 578.43% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $693000.0 at ClearPoint Neuro, down from $938000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.7 million in Q4 2024 and bottomed at -$2.9 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $374000.0 (2023), against an average of $214789.5.
  • The largest YoY upside for Change in Accured Expenses was 443.4% in 2022 against a maximum downside of 1181.48% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$133000.0 in 2021, then surged by 352.63% to $336000.0 in 2022, then rose by 11.31% to $374000.0 in 2023, then skyrocketed by 363.1% to $1.7 million in 2024, then tumbled by 59.99% to $693000.0 in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Change in Accured Expenses are $693000.0 (Q3 2025), $938000.0 (Q2 2025), and -$2.9 million (Q1 2025).